Legal entity
Last mentioned: Mar 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, corporate-law. Fermi Inc is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 4 original sources per story, versus 2.8 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6.4. Navan, Inc. appears in 1 tracked Legal story from March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 56 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Navan, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Lead Plaintiff Deadline
Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.
Market Reaction
Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.
Investor Alerts Issued
Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.
Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.
Source: prnewswire.com · prnewswire.com
Navan, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
